Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Victoria

$50,000.00

Detection of SARS-CoV-2 virus structural proteins as an aid to diagnosis and monitoring of COVID-19_x000d_ _x000d_ _x000d_

EF 2020-21

Résumé
It has recently become clear that COVID-19 is not just a respiratory disease but also an illness that can affect multiple organs since there are receptors for the causative virus throughout the human body. There is a need for tools to study the presence of the causative virus and its effects on various physiological and immunological systems of the human host to enable better strategies for COVID-19 control. Herein we focus on development of highly sensitive and accurate tests for detecting and quantitating the main structural proteins of the SARS-CoV-2 virus and selected human proteins to allow measurement of host biomarker responses. The foundation of our approach is Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA), a technology that offers sensitive measurement of biomarkers indicative of disease; in this case the virus proteins themselves and host proteins that change in response to viral infection of different cells and organs. This technology allows inexpensive, multiplexed biomarker measurement in complex biological fluids such as whole blood, plasma, serum and saliva. SISCAPA technology will allow direct measurement of the SARS-CoV-2 virus proteins and thus determination of active infections, the gold standard for diagnosis of infectious diseases. Current diagnostic tests using the standard polymerase chain reaction (PCR) only detect genetic material from the virus, not the assembled viruses themselves. Although PCR tests are excellent for population screening, they are prone to false negative and false positive results, thus a separate test that measures structural components of the virus will complement diagnosis by PCR, allowing a better understanding of the disease state. Since SISCAPA technology uses enzyme-digested blood and saliva samples, virus-specific host antibodies that interfere with standard immunoassays are destroyed, allowing accurate detection of virus proteins. In addition to measurement of the SARS-CoV-2 virus, multiplexed SISCAPA measurement of host proteins produced in response to virus infection will yield information about the infection process, thus offering strategies for treatment and control of COVID-19.
Programme
Alliance Grants
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
552858-2020
Name nom
Cameron, Caroline
Department département
Biochemistry and Microbiology
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
5202
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Virology
Research subject fr
Virologie
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Detection of SARS-CoV-2 virus structural proteins as an aid to diagnosis and monitoring of COVID-19_x000d_ _x000d_ _x000d_
Keyword
NSERC
Application summary
It has recently become clear that COVID-19 is not just a respiratory disease but also an illness that can affect multiple organs since there are receptors for the causative virus throughout the human body. There is a need for tools to study the presence of the causative virus and its effects on various physiological and immunological systems of the human host to enable better strategies for COVID-19 control. Herein we focus on development of highly sensitive and accurate tests for detecting and quantitating the main structural proteins of the SARS-CoV-2 virus and selected human proteins to allow measurement of host biomarker responses. The foundation of our approach is Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA), a technology that offers sensitive measurement of biomarkers indicative of disease; in this case the virus proteins themselves and host proteins that change in response to viral infection of different cells and organs. This technology allows inexpensive, multiplexed biomarker measurement in complex biological fluids such as whole blood, plasma, serum and saliva. SISCAPA technology will allow direct measurement of the SARS-CoV-2 virus proteins and thus determination of active infections, the gold standard for diagnosis of infectious diseases. Current diagnostic tests using the standard polymerase chain reaction (PCR) only detect genetic material from the virus, not the assembled viruses themselves. Although PCR tests are excellent for population screening, they are prone to false negative and false positive results, thus a separate test that measures structural components of the virus will complement diagnosis by PCR, allowing a better understanding of the disease state. Since SISCAPA technology uses enzyme-digested blood and saliva samples, virus-specific host antibodies that interfere with standard immunoassays are destroyed, allowing accurate detection of virus proteins. In addition to measurement of the SARS-CoV-2 virus, multiplexed SISCAPA measurement of host proteins produced in response to virus infection will yield information about the infection process, thus offering strategies for treatment and control of COVID-19.